文献速递肝病

原发性胆汁性胆管炎患病率上升且治疗可降低死亡率

Increasing Prevalence of Primary Biliary Cholangitis and Reduced Mortality With Treatment.
PubMed 文献 · Clin Gastroenterol Hepatol · 2017-12-23

该研究基于美国Fibrotic Liver Disease联盟11个卫生系统2003至2014年常规诊疗数据,纳入3488例原发性胆汁性胆管炎(PBC)患者,分析患病率与发病率趋势及死亡影响因素。结果显示2006至2014年患病率从21.7升至39.2/10万人,发病率无显著变化,熊去氧胆酸(UDCA)治疗与死亡率显著降低相关(aHR 0.57)。

要点

  • 2006至2014年PBC患病率从21.7升至39.2/10万人,发病率无显著变化。
  • 女性与男性患病率比为3.9:1,发病率比为3.2:1,研究期间保持一致。
  • UDCA治疗与死亡率显著降低相关(aHR 0.57;95%CI 0.52-0.64)。

核心结论

  • 在Fibrotic Liver Disease联盟卫生系统常规诊疗患者中,PBC患病率从2004年至2014年上升,而发病率保持稳定。
  • 患者人口学与临床特征以及UDCA治疗均影响死亡率。

研究设计与样本

  • 研究收集2003年1月1日至2014年12月31日美国东北部、中西部、西北部和南部11个卫生系统常规诊疗的PBC患者及一般人群人口学与临床数据。
  • 采用join-point泊松回归估计PBC患病率与发病率的年度百分比变化,以率比计算种族、年龄和性别差异。
  • 采用Cox回归估计全因死亡率并校正患者特征与UDCA治疗,使用倾向评分校正治疗选择偏倚,分析按地理区域校正。

主要发现

  • 在3488例种族多样PBC患者(21%西班牙裔、8%非裔美国人、7%亚裔美国人)中,70%曾接受UDCA治疗。
  • 2006年至2014年PBC患病率从21.7升至39.2/10万人;不同年龄组(≤40岁、41-50岁、51-60岁、61-70岁、>70岁)校正后年度百分比变化范围为3.0%至7.5%(P < .05)。
  • 研究期间发病率无显著变化(2006年4.2 vs 2014年4.3/10万人年;P = .98)。
  • 女性与男性患病率比为3.9:1、发病率比为3.2:1,研究期间保持一致;非裔美国人患病率从16.9升至30.8/10万人,年发病率范围为2.6至6.6/10万人年。
  • 校正分析中,基线碱性磷酸酶水平升高与死亡率显著升高相关:1-2倍正常上限者aHR 1.24(95%CI 1.04-1.48),超过3倍正常上限者aHR 2.27(95%CI 1.88-2.73);UDCA治疗与死亡率显著降低相关(aHR 0.57;95%CI 0.52-0.64)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND & AIMS: There are few data from longitudinal studies of trends in primary biliary cholangitis (PBC) among patients under routine clinical care in the United States. We collected data from the Fibrotic Liver Disease consortium to investigate changes in the incidence and prevalence of PBC and the effects of patient demographics, clinical features, and treatment on mortality. METHODS: We collected demographic and clinical data for the general patient population as well as PBC patients receiving care from 11 health systems in different regions of the United States (Northeast, Midwest, Northwest, and South) from January 1, 2003, through December 31, 2014. Annual percentage changes in PBC prevalence and incidence were estimated using join-point Poisson regression. Differences based on race, age, and gender were calculated with rate ratios. All-cause mortality was estimated using Cox regression with adjustment for patient characteristics and treatment with ursodeoxycholic acid (UDCA). Propensity scores were used to adjust for treatment selection bias. Analyses were adjusted by geographic regions. RESULTS: In our racially diverse cohort of 3488 patients with PBC (21% Hispanic, 8% African American, 7% Asian American), 70% had ever received UDCA. From 2006 through 2014, the prevalence of PBC increased from 21.7 to 39.2 per 100,000 persons. Adjusted annual percentage changes in prevalence differed among age groups (≤40 y, 41-50 y, 51-60 y, 61-70 y, and >70 y), ranging from 3.0% to 7.5% (P < .05). Incidence did not change significantly during the study period (4.2 vs 4.3 per 100,000 person-years in 2006 and 2014, respectively; P = .98). Ratios of prevalence for women vs men (3.9:1) and incidence for women vs men (3.2:1) were consistent over the study period. Among African Americans, the prevalence of PBC increased from 16.9 to 30.8 per 100,000 during the study period, and annual incidence ranged from 2.6 to 6.6 per 100,000 person-years. In adjusted analyses, an increased level of alkaline phosphatase at baseline was associated with significantly higher mortality (adjusted hazard ratios [aHR], 1.24; 95% CI, 1.04-1.48 for patients with levels 1-2 times the upper limit of normal and aHR, 2.27; 95% CI, 1.88-2.73 for patients with levels more than 3 times the upper limit of normal). UDCA treatment was associated with significantly reduced mortality (aHR, 0.57; 95% CI, 0.52-0.64). CONCLUSIONS: In an analysis of data from patients receiving routine clinical care in Fibrotic Liver Disease Consortium health systems, we found that the prevalence of PBC increased from 2004 through 2014, despite steady incidence. Patient demographic and clinical characteristics, as well as UDCA treatment, affected mortality.

来源:Clin Gastroenterol Hepatol,查看原文。版权归原作者所有。

引用

  1. Lu M, Zhou Y, Haller IV, et al. Increasing Prevalence of Primary Biliary Cholangitis and Reduced Mortality With Treatment. Clin Gastroenterol Hepatol. 2017. PMID: 29277621. doi:10.1016/j.cgh.2017.12.033

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。